Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 4/2013

01-08-2013 | Editorial

The present state of health economics: a critique and an agenda for the future

Author: Peter Zweifel

Published in: The European Journal of Health Economics | Issue 4/2013

Login to get access

Excerpt

A couple of days ago, I was asked to give an interview concerning the conference ECHE 2012, the motto of which was, “Progress in Health Economics”. One of the questions posed to me was, “What is your vision of Health Economics 10 years from now?” Here is what I had to say. …
Literature
1.
Beck, K., Zweifel, P., Trottmann, M.: Risk adjustment in health insurance and its long-term effectiveness. J. Health Econ. 29(4), 489–498 (2010)PubMedCrossRef
2.
Eugster, P., Sennhauser, M., Zweifel, P.: Capping risk adjustment? J. Health Econ. 29(4), 499–507 (2010)PubMedCrossRef
3.
Kifmann, M., Roeder, K.: Premium subsidies and social health insurance: substitutes or complements? J. Health Econ. 30(6), 1207–1218 (2012)CrossRef
4.
Schoder, J., Sennhauser, M., Zweifel, P.: Fine-tuning of health insurance regulation—unhealthy consequences for an individual insurer. Int. J. Econ. Bus. 17(3), 313–327 (2010)CrossRef
5.
Sennhauser, M., Zweifel, P.: Ist ein neues Arzneimittel sein Geld wert? Wessen Geld? Submitted for publication in the German special edition of Pharmaco Econ (2012). Also available from the authors as: a new pharmaceutical: is it worth the money? Whose money?
6.
Van de Ven, W., Ellis, R.: Risk adjustment in competitive health plan markets. In: Newhouse, J.P., Culyer, A.J. (eds.) Handbook of Health Economics, vol. 1A, pp. 755–845. North-Holland, Amsterdam (2000)
7.
Zweifel, P. (ed.): Health, regulation, and the medical profession. Developments in health economics and public policy. Kluwer/Springer, Boston (1998)
8.
Zweifel, P., Breuer, M.: The case for risk-based premiums in public health insurance. Health Econ. Policy Law 1(2), 171–188 (2006)PubMedCrossRef
Metadata
Title
The present state of health economics: a critique and an agenda for the future
Author
Peter Zweifel
Publication date
01-08-2013
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 4/2013
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-012-0427-2

Other articles of this Issue 4/2013

The European Journal of Health Economics 4/2013 Go to the issue

Original Paper

The effect of stimulants and their combined use with cigarettes on mortality: the case of betel quid

Original Paper

Measuring Worksite Health Promotion Programs: an application of Structural Equation Modeling with ordinal data

Original Paper

The effect of chronic conditions on stated preferences for health

Original Paper

Assessing the impact of national antibiotic campaigns in Europe

Original Paper

Competition in prescription drug markets: the roles of trademarks, advertising, and generic names

Original Paper

What accounts for the regional differences in the utilisation of hospitals in Germany?